Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial

BACKGROUND: Dolutegravir (DTG)–based dual therapy is becoming a new paradigm for both the initiation and maintenance of HIV treatment. The SIMPL’HIV study investigated the outcomes of virologically suppressed patients on standard combination antiretroviral therapy (cART) switching to DTG + emtricita...

Descripción completa

Detalles Bibliográficos
Autores principales: Sculier, Delphine, Wandeler, Gilles, Yerly, Sabine, Marinosci, Annalisa, Stoeckle, Marcel, Bernasconi, Enos, Braun, Dominique L., Vernazza, Pietro, Cavassini, Matthias, Buzzi, Marta, Metzner, Karin J., Decosterd, Laurent A., Günthard, Huldrych F., Schmid, Patrick, Limacher, Andreas, Egger, Matthias, Calmy, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654764/
https://www.ncbi.nlm.nih.gov/pubmed/33170863
http://dx.doi.org/10.1371/journal.pmed.1003421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654764/
https://www.ncbi.nlm.nih.gov/pubmed/33170863
http://dx.doi.org/10.1371/journal.pmed.1003421

Ejemplares similares